Chicago-based Maia Biotechnology said this week that its lead drug candidate, THIO, has gained its generic name, and preclinical data on a different form of the cancer drug suggests it could ...

In a preclinical study, THIO and its new described dimer form were found to be potent inhibitors of Glutathione S-transferase Pi (GSTP1), a key enzyme implicated in cancer progression and ...

Ether is struggling to reverse a near three-month downtrend as macroeconomic concerns and continued selling pressure from US Ether exchange-traded funds (ETFs) weigh on investor sentiment.

“The designation of a new nonproprietary name for THIO is a key step along our development and regulatory pathway as we move forward with phase 2 and 3 clinical trials,” said Vlad Vitoc, M.D., CEO of ...

CHICAGO, March 20, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company ...

An ether (ETH) position worth more than $126 million came within 4% of being liquidated amid a crypto market plunge on Tuesday. ETH has now retraced more than the entirety of Sunday's rally ...

“The designation of a new nonproprietary name for THIO is a key step along our development and regulatory pathway as we move forward with Phase 2 and 3 clinical trials,” said Vlad ...

The blockchain platform linked to United States President Donald Trump took the crypto market downturn as an investment opportunity, tripling its Ether holdings in a week ahead of the White House ...

Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard cancer treatments and overcoming resistance MAIA Biotechnology, Inc., (NYSE American ...

National securities exchange Cboe is asking the U.S. Securities and Exchange Commission (SEC) to allow staking in several spot ether (ETH) exchange-traded funds (ETFs), sending the price of token ...